APR 2 5 2003 & APR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

William J. Curatolo, et al.

Group Art Unit: 1615 Examiner: B. M. Fubara

PATENT NO.: 09/918,127

s being deposited with the United States Postal Service as First Class Mail in an

FOR: Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor:

Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner

PC10754

FILED: July 30, 2001

for Patents, Washington, D.C. 20231 on

-- 62

Assistant Commissioner For Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 CFR 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: April 22 2003

James T. Jones

Attorney for Applicant(s)

Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4903